Highlights From ASCO 2022
Ribociclib Breast Cancer Presentations
MONALEESA-2 OS BY DOSE REDUCTION poster discussion | Hart LL In this exploratory analysis of ML-2, 1L RIB + LET maintained OS benefit in postmenopausal pts with HR+, HER2...
MONALEESA-2 OS BY DOSE REDUCTION poster discussion | Hart LL In this exploratory analysis of ML-2, 1L RIB + LET maintained OS benefit in postmenopausal pts with HR+, HER2...
Two phase III, randomised, double-blind, placebo-controlled studies RAISE (TRA102537) and TRA100773B and two open-label studies REPEAT (TRA108057) and EXTEND (TRA105325)...